CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 38 filers reported holding CUE BIOPHARMA INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $276,556 | -45.3% | 146,326 | -23.6% | 0.00% | – |
| Q4 2023 | $505,655 | +14.8% | 191,536 | 0.0% | 0.00% | – |
| Q3 2023 | $440,533 | -17.5% | 191,536 | +30.9% | 0.00% | – |
| Q2 2023 | $534,090 | -19.0% | 146,326 | +24.7% | 0.00% | – |
| Q1 2022 | $659,000 | -24.1% | 117,327 | +40.8% | 0.00% | – |
| Q4 2021 | $868,000 | -28.9% | 83,321 | -11.9% | 0.00% | – |
| Q3 2021 | $1,220,000 | +8.8% | 94,543 | -1.8% | 0.00% | – |
| Q2 2021 | $1,121,000 | -10.5% | 96,245 | -6.3% | 0.00% | – |
| Q1 2021 | $1,252,000 | -29.7% | 102,669 | -27.9% | 0.00% | -100.0% |
| Q4 2020 | $1,781,000 | -16.3% | 142,361 | +0.6% | 0.00% | 0.0% |
| Q3 2020 | $2,129,000 | -40.0% | 141,450 | -2.3% | 0.00% | 0.0% |
| Q2 2020 | $3,550,000 | +189.1% | 144,838 | +67.3% | 0.00% | 0.0% |
| Q1 2020 | $1,228,000 | -40.9% | 86,559 | -33.8% | 0.00% | 0.0% |
| Q4 2019 | $2,077,000 | +252.0% | 130,779 | +86.9% | 0.00% | – |
| Q3 2019 | $590,000 | +3.5% | 69,954 | +10.4% | 0.00% | – |
| Q2 2019 | $570,000 | – | 63,349 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Slate Path Capital LP | 890,000 | $7,503,000 | 0.50% |
| Nantahala Capital Management | 1,378,198 | $11,618,000 | 0.43% |
| 683 Capital Management, LLC | 300,000 | $2,529,000 | 0.28% |
| Rock Creek Group, LP | 42,505 | $358,000 | 0.17% |
| SPHERA FUNDS MANAGEMENT LTD. | 50,000 | $422,000 | 0.06% |
| Parian Global Management LP | 11,000 | $93,000 | 0.04% |
| Sigma Planning Corp | 60,210 | $508,000 | 0.02% |
| D'Orazio & Associates, Inc. | 2,000 | $17,000 | 0.01% |
| OXFORD ASSET MANAGEMENT LLP | 26,602 | $224,000 | 0.01% |
| STIFEL FINANCIAL CORP | 55,855 | $471,000 | 0.00% |